Lian Brian
SEC CIK 1614578 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | Pres, CEO, Dir | 2.57M | — | $74.66M | 47 | 2021-09-28 | 2026-07-29 |
Most active insiders at VKTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lian Brian | Pres, CEO, Dir | — | $14.01M |
| 2 | ZANTE GREG | CFO | — | $2.82M |
| 3 | Mancini Marianna | COO | — | $2.73M |
| 4 | Rowland Charles A Jr | Dir | — | $2.13M |
| 5 | FOEHR MATTHEW W | Dir | — | $561.8K |
| 6 | Aubuchon Neil William | Chief Commercial Off | $149.9K | — |
| 7 | Kelly-Gemmell Dorothy Elizabeth | Dir | — | — |
| 8 | Rouan Sarah Kathryn | Dir | — | — |
| 9 | MACARTNEY LAWSON | Dir | — | — |
| 10 | SINGLETON J MATTHEW | Dir | — | — |
Transactions 47
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 20:07 | 2026-07-28 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +221.7K | 2.72M | +9% | $0 | |
| 2026-07-29 20:07 | 2026-07-29 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $33.32 | -148.5K | 2.57M | -5% | -$4.95M | |
| DM | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +302.5K | 2.51M | +14% | $0 |
| DM | 2026-01-05 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $32.96 | -233.4K | 2.60M | -8% | -$7.69M |
| 2025-10-28 | 2025-10-27 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +70.1K | 2.46M | +3% | $0 | |
| 2025-10-28 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $35.01 | -39.0K | 2.42M | -2% | -$1.37M | |
| 2025-07-03 | 2025-07-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $27.80 | -26.9K | 2.39M | -1% | -$747.5K | |
| 2025-07-03 | 2025-07-02 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +48.3K | 2.41M | +2% | $0 | |
| DM | 2025-01-06 | 2025-01-06 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $42.74 | -194.5K | 2.39M | -8% | -$8.31M |
| DM | 2025-01-06 | 2025-01-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +256.1K | 2.56M | +11% | $0 |
| DMT | 2024-09-20 | 2024-09-20 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $70.83 | -216.1K | 2.43M | -8% | -$15.31M |
| DT | 2024-09-20 | 2024-09-20 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $7.77 | +166.1K | 2.52M | +7% | +$1.29M |
| DT | 2024-08-22 | 2024-08-21 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $69.90 | -1,000 | 2.35M | -0.0% | -$69.9K |
| DT | 2024-08-22 | 2024-08-21 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $7.77 | +1,000 | 2.36M | +0.0% | +$7,770 |
| DMT | 2024-08-19 | 2024-08-19 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $65.80 | -112.9K | 2.35M | -5% | -$7.43M |
| DT | 2024-08-19 | 2024-08-19 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $7.77 | +112.9K | 2.47M | +5% | +$877.0K |
| M | 2024-07-31 | 2024-07-29 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +204.3K | 2.47M | +9% | $0 |
| M | 2024-07-31 | 2024-07-30 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $57.58 | -115.9K | 2.35M | -5% | -$6.67M |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +221.7K | 2.42M | +10% | $0 | |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $83.34 | -153.9K | 2.27M | -6% | -$12.83M | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $85.22 | -162.8K | 2.20M | -7% | -$13.88M | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +221.7K | 2.36M | +10% | $0 | |
| 2024-02-09 | 2024-02-09 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $29.90 | -45.0K | 2.14M | -2% | -$1.35M | |
| DM | 2024-02-08 | 2024-02-08 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $26.87 | -269.1K | 2.26M | -11% | -$7.23M |
| DM | 2024-02-08 | 2024-02-08 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $3.76 | +189.1K | 2.31M | +9% | +$711.4K |
| DM | 2024-01-31 | 2024-01-31 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $24.71 | -85.0K | 2.26M | -4% | -$2.10M |
| D | 2024-01-31 | 2024-01-31 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $1.23 | +85.0K | 2.35M | +4% | +$104.5K |
| D | 2024-01-30 | 2024-01-30 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $1.23 | +35.0K | 2.30M | +2% | +$43.0K |
| D | 2024-01-30 | 2024-01-30 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $23.95 | -35.0K | 2.26M | -2% | -$838.2K |
| DM | 2024-01-04 | 2024-01-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +310.0K | 2.41M | +15% | $0 |
| DM | 2024-01-04 | 2024-01-03+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $17.58 | -254.2K | 2.26M | -10% | -$4.47M |
| 2023-05-01 | 2023-05-01 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $22.45 | -45.0K | 2.20M | -2% | -$1.01M | |
| 2023-04-21 | 2023-04-19 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale | $21.45 | -35.0K | 2.24M | -2% | -$750.8K | |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $20.45 | -155.0K | 2.28M | -6% | -$3.17M |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $2.15 | +125.0K | 2.43M | +5% | +$268.8K |
| D | 2023-04-13 | 2023-04-13 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $18.45 | -79.3K | 2.31M | -3% | -$1.46M |
| D | 2023-04-13 | 2023-04-13 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $1.88 | +54.3K | 2.39M | +2% | +$102.2K |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | M - OptEx | $4.78 | +203.4K | 2.32M | +10% | +$972.9K |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $17.31 | -243.4K | 2.23M | -10% | -$4.21M |
| D | 2023-04-03 | 2023-04-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +300.0K | 2.53M | +13% | $0 |
| D | 2023-04-03 | 2023-04-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $17.57 | -200.0K | 2.33M | -8% | -$3.51M |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +388.3K | 2.37M | +20% | $0 |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $8.86 | -163.0K | 2.27M | -7% | -$1.44M |
| DM | 2022-01-05 | 2022-01-03+ | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $4.77 | -62.8K | 1.89M | -3% | -$299.4K |
| D | 2022-01-05 | 2022-01-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +173.3K | 2.06M | +9% | $0 |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | F - Tax | $6.50 | -27.8K | 1.92M | -1% | -$180.4K | |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +55.5K | 1.95M | +3% | $0 |
Purchase Sale Sale after option exercise All abbreviations